| Dr Dennis Peter Burke, MD | |
|
3264 N Evergreen Dr Ne, Grand Rapids, MI 49525-9746 | |
| (616) 363-7272 | |
| (616) 363-7290 |
| Full Name | Dr Dennis Peter Burke |
|---|---|
| Gender | Male |
| Speciality | Radiology - Diagnostic Radiology |
| Location | 3264 N Evergreen Dr Ne, Grand Rapids, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194740415 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 4301036590 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dennis Peter Burke, MD 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525-9746 Ph: (616) 363-7272 | Dr Dennis Peter Burke, MD 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525-9746 Ph: (616) 363-7272 |
News Archive
DiscoveryBioMed, Inc. (DBM), a human cell-based drug discovery company, learned recently that its Cystic Fibrosis Corrector Ligand (CFCL) Drug Discovery program will be funded by the NIH. The two-year award will focus on validation and prioritization of several lead CFCL chemical classes, drugs that correct the most common cystic fibrosis (CF) disease-causing mutation.
Almost four out of five Australians (78%) report that they look for information about medicines on the internet, according to a new 2016 survey* released during Be Medicinewise Week (22-28 August).
A meta-analysis of previous research suggests that use of pioglitazone, a glycemic control medication for patients with type 2 diabetes, significantly reduces the risk of heart attack, stroke and death, but increases the risk for serious heart failure, according to an article in the September 12 issue of JAMA: The Journal of the American Medical Association.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer (CRC).
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.
› Verified 2 days ago
Dr. Jon R Henke, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 Fax: 616-363-7290 | |
Geoffrey M. Remes, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7339 Fax: 616-361-5828 | |
Jan L Mourelatos, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 Fax: 616-361-5828 | |
Dr. Brendan Michael Banyon, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 | |
Dr. Joseph J Junewick, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 Fax: 616-363-7290 | |
Keith Alan Morrow, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7339 Fax: 616-361-5828 | |
Dr. Andrew Kent Moriarity, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7339 |